Page 7 - பூமா உயிரி தொழில்நுட்பவியல் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Search jobs 11-Dec-2020 Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS Results show continued efficacy of neratinib in patients with HER2-positive early stage breast cancer LOS ANGELES, Calif., December 11, 2020 / B3C newswire / Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial were presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. The presentation entitled, “Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial,” is being presented at a Spotlight Poster Discussion Session by Frankie Ann Holmes, M.D., FACP, Texas Oncology Houston – US Oncology Research, an

United statesFrankie ann holmesMaggie bellerAlanh auerbachPuma biotechnology incEuropean unionEuropean commissionDrug administrationUs oncology researchPuma biotechnologySan antonio breast cancer symposiumSpotlight poster discussion sessionTexas oncology houstonClinical breastChief executive officerControl poster